AGEN
Price
$0.78
Change
-$0.02 (-2.50%)
Updated
Dec 6, 6:59 PM EST
98 days until earnings call
INO
Price
$0.38
Change
-$0.02 (-5.00%)
Updated
Dec 6, 6:59 PM EST
97 days until earnings call
Ad is loading...

Analysis and predictions AGEN vs INO

Header iconAGEN vs INO Comparison
Open Charts AGEN vs INOBanner chart's image
Agenus
Price$0.78
Change-$0.02 (-2.50%)
Volume$13.91M
CapitalizationN/A
Inovio Pharmaceuticals
Price$0.38
Change-$0.02 (-5.00%)
Volume$1.45M
CapitalizationN/A
View a ticker or compare two or three
AGEN vs INO Comparison Chart

Loading...

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
VS
AGEN vs. INO commentary
Dec 07, 2023

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AGEN is a StrongSell and INO is a Hold.

COMPARISON
Comparison
Dec 07, 2023
Stock price -- (AGEN: $0.78 vs. INO: $0.38)
Brand notoriety: AGEN: Not notable vs. INO: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AGEN: 214% vs. INO: 56%
Market capitalization -- AGEN: $251.9M vs. INO: $111.92M
AGEN [@Biotechnology] is valued at $251.9M. INO’s [@Biotechnology] market capitalization is $111.92M. The market cap for tickers in the [@Biotechnology] industry ranges from $464.61B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AGEN’s FA Score shows that 0 FA rating(s) are green whileINO’s FA Score has 0 green FA rating(s).

  • AGEN’s FA Score: 0 green, 5 red.
  • INO’s FA Score: 0 green, 5 red.
According to our system of comparison, AGEN is a better buy in the long-term than INO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AGEN’s TA Score shows that 4 TA indicator(s) are bullish while INO’s TA Score has 1 bullish TA indicator(s).

  • AGEN’s TA Score: 4 bullish, 4 bearish.
  • INO’s TA Score: 1 bullish, 8 bearish.
According to our system of comparison, AGEN is a better buy in the short-term than INO.

Price Growth

AGEN (@Biotechnology) experienced а +11.55% price change this week, while INO (@Biotechnology) price change was +0.32% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.65%. For the same industry, the average monthly price growth was +5.77%, and the average quarterly price growth was +27.21%.

Reported Earning Dates

AGEN is expected to report earnings on Mar 14, 2024.

INO is expected to report earnings on Mar 13, 2024.

Industries' Descriptions

@Biotechnology (+6.65% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for AGEN with price predictions.
OPEN
A.I.dvisor published
a Summary for INO with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
AGEN($252M) has a higher market cap than INO($112M). AGEN YTD gains are higher at: -66.817 vs. INO (-75.673). INO has higher annual earnings (EBITDA): -158.65M vs. AGEN (-201.61M). INO has more cash in the bank: 167M vs. AGEN (106M). INO has less debt than AGEN: INO (29.8M) vs AGEN (89M). AGEN has higher revenues than INO: AGEN (101M) vs INO (854K).
AGENINOAGEN / INO
Capitalization252M112M225%
EBITDA-201.61M-158.65M127%
Gain YTD-66.817-75.67388%
P/E Ratio12.89N/A-
Revenue101M854K11,827%
Total Cash106M167M63%
Total Debt89M29.8M299%
FUNDAMENTALS RATINGS
AGEN vs INO: Fundamental Ratings
AGEN
INO
OUTLOOK RATING
1..100
83
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
51
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
6579
P/E GROWTH RATING
1..100
58100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

INO's Valuation (51) in the Medical Specialties industry is somewhat better than the same rating for AGEN (97) in the Biotechnology industry. This means that INO’s stock grew somewhat faster than AGEN’s over the last 12 months.

INO's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as AGEN (100) in the Biotechnology industry. This means that INO’s stock grew similarly to AGEN’s over the last 12 months.

INO's SMR Rating (98) in the Medical Specialties industry is in the same range as AGEN (100) in the Biotechnology industry. This means that INO’s stock grew similarly to AGEN’s over the last 12 months.

AGEN's Price Growth Rating (65) in the Biotechnology industry is in the same range as INO (79) in the Medical Specialties industry. This means that AGEN’s stock grew similarly to INO’s over the last 12 months.

AGEN's P/E Growth Rating (58) in the Biotechnology industry is somewhat better than the same rating for INO (100) in the Medical Specialties industry. This means that AGEN’s stock grew somewhat faster than INO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AGENINO
RSI
ODDS (%)
Bullish Trend 1 day ago
88%
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 1 day ago
78%
Bearish Trend 1 day ago
88%
MACD
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
85%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
77%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
87%
Advances
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 4 days ago
75%
Declines
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
87%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
85%
Aroon
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
82%
View a ticker or compare two or three
Ad is loading...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LMGFX56.46-0.04
-0.07%
ClearBridge International Growth FI
VYMVX16.38-0.03
-0.18%
Voya Mid Cap Research Enhanced Index R
CGRIX54.41-0.34
-0.62%
Calamos Growth I
HWMZX49.76-0.46
-0.92%
Hotchkis & Wiley Mid Cap Value Z
GAGEX23.58-0.48
-2.00%
Guinness Atkinson Global Energy

AGEN and

Correlation & Price change

A.I.dvisor indicates that over the last year, AGEN has been loosely correlated with NTLA. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if AGEN jumps, then NTLA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AGEN
1D Price
Change %
AGEN100%
-2.20%
NTLA - AGEN
52%
Loosely correlated
-0.17%
BEAM - AGEN
49%
Loosely correlated
+1.49%
AGIO - AGEN
49%
Loosely correlated
+0.09%
CRSP - AGEN
49%
Loosely correlated
+0.77%
DNLI - AGEN
49%
Loosely correlated
+3.24%
More